Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financi... (consequently cell function. Sangam...)

Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results

Date:2/3/2010

consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/.

This press release contains forward-looking statements regarding Sangamo's current expectations. These forward looking statements include, without limitation, references to the research and development of ZFP TFs and ZFNs, clinical trials and therapeutic applications of Sangamo's ZFP technology platform, achievement of research milestones and objectives, strategic partnership and commercial license agreements with collaborators, presentation of data from research collaborations and anticipated cash and investments balance. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the early stage of ZFP Therapeutic development, uncertainties related to the timing of initiation and completion of clinical trials, whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics, and the ability to establish strategic partnerships. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo will be able to develop commercially viable gene based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related biology technology :

1. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
2. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
3. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
4. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
5. Sangamo Announces Pricing of Public Offering of Common Stock
6. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
7. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
8. Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells
9. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
10. Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
11. Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference

Post Your Comments:

(Date:5/17/2013)... transplant rejection occurs when the transplant recipient,s immune system ... it. It was previously thought that T cells, the ... by molecules known as chemokines in order to migrate ... Journal of Clinical Investigation , Fadi Lakkis and ... demonstrate that chemokine stimulation of T cells is not ...

(Date:5/17/2013)... The new Public-Private Partnership (PPP) in ... association’s recent annual meeting drew praise from community leaders ... who called the action “a huge step forward … ... European innovation.” , The Board of Stakeholders voted to ... PPP at its 29 April meeting in Brussels, which ...

(Date:5/17/2013)... May 17, 2013 Cellular Biomedicine Group (OTCQB: ... enrollment of the total projected enrollment required for ... and preliminary efficacy of the medical technology haMPC ... Osteoarthritis (KOA). To date the trial has had ... The Phase I open label clinical research trial ...

(Date:5/17/2013)... Insero Health, Inc., a company developing natural compounds ... neurological disorders, is today reporting top-line results from a ... patients with drug-resistant epilepsy. The data are being presented ... meeting by Dr. Steven Schachter , ... Advisory Board. In this study, INS001 appeared safe and ...

Breaking Biology Technology:SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2 SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3 Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2 Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2

[0] Researchers identify signals that direct the immune system to reject a transplanted organ [0] SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions [0] Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis [0] Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy

... Sonia Moralejo Garca at the University of the Basque Country ... and other magnetic devices of wide industrial application. , It ... that are ever smaller and that nanotechnology, although it its ... in our society. Who has not heard of nanotubes, nanoparticles ...

... INCREASE 14.6%. Q4 2007 DILUTED EPS UP 20.8% TO $.64. 2008 ... $2.62 PER SHARE., ST. LOUIS, Feb. 12 , HIGHLIGHTS: ... -- Q4 2007 Sales Set New Quarterly Record: At $532.1 ... high, beating the Q2 2007 record of $507.5 ...

... of Dow AgroSciences Announces Milestone in Wall Street ... ,Dow AgroSciences LLC and Sangamo BioSciences, Inc. (Nasdaq: ... a key research milestone as part of,their joint ... successful application of Sangamo,s zinc finger DNA-binding,protein nuclease ...

A researcher of UPV/EHU has designed nanomagnets for industry Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark.Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestone in Plant Agriculture Collaboration

(Date:5/18/2013)... FL (May 18, 2013) Research presented at ... managing digestive health through diet and lifestyle. ... plagued by reduced muscle strength, fatigue and poor ... when patients are in remission. A randomized, double ... that vitamin D supplementation corresponded to significant relief ...

(Date:5/17/2013)... provide the white noise of the South, but the night ... Southern air hangs heavy from the humidity and the sounds ... 140 species of frogs, toads and salamanders, is the center ... and swamps are the auditorium for their symphonic choruses, the ... Initiative, or ARMI, have front-row seats. , Amphibians, ...

(Date:5/17/2013)... proteins in the brain responsible for protecting nerve cells ... increase cell survival. , The discovery, made by researchers ... the EMBO journal with additional comment in ... stroke and other brain diseases. , The research builds ... protein, known as SUMO, responsible for controlling the chemical ...

Breaking Biology News(10 mins):Research examines new methods for managing digestive health 2 Research examines new methods for managing digestive health 3 Front-row seats to climate change 2 Front-row seats to climate change 3 Front-row seats to climate change 4 SUMO wrestling cells reveal new protective mechanism target for stroke 2

[0] Research examines new methods for managing digestive health [0] Front-row seats to climate change [0] SUMO wrestling cells reveal new protective mechanism target for stroke

... A new study, led by Felix Aigner, M.D., ... as potentially responsible for regulating the body's inflammatory ... complications involved with many transplantations is the damage ... following surgery, known as ischemia and reperfusion (IR). ...

... major role in deadly prion diseases by smashing up ... allow fatal brain illnesses to quickly spread, new Brown ... say, because they might reveal a way to control ... drug could be made that inhibits this fragmentation process, ...

... The costs due to complications from preterm birth are ... preterm infants are estimated to be almost $2 billion ... researchers found that giving nitroglycerin to mothers who had ... baby’s health. The results of the study are reported ...

Cached Biology News:Brown team finds crucial protein role in deadly prion spread 2

Protein may hold key to decreasing organ dysfunction rates in heart transplants Brown team finds crucial protein role in deadly prion spread Plastic that degrades in seawater could be boon for cruise industry and others

...

Rat Antibody to Kinase Suppressor Of Ras Recognises the kinase suppressor of Ras (KSR). Immunogen: Recombinant human KSR protein Specificity: human kinase supressor of Ras...

Request Info...

NATIVE RAT OSTEOCALCIN...

Biology Products:

Mouse Granzyme B ELISpot Kit from R&D Systems Rat Anti-Kinase Suppressor Of Ras Monoclonal Antibody, Unconjugated, Clone MINT/1/4 from GeneTex 8 Channel Syringe Dispenser, 20 cc Capacity from Biosearch Technologies Rat OSTEOCALCIN Native from AbD Serotec